OXYGEN THERAPY

Phase 1Small molecule

MMassachusetts General Hospital

OXYGEN THERAPY is one of 73 small molecule programs targeting Kidney Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney DiseaseActive, not recruiting

Pulmonary EmbolismRecruiting

Kidney DiseasePreclinical

Active, not recruiting

Pulmonary EmbolismPhase 1

Recruiting

Competition

Competitive Landscape

105 competitors in Kidney Disease

#DrugCompanyPhaseTrials

Zyloprim

Nexavar

Kisqali

Maxipime

Afinitor

Medrol

Norvir

Xtandi

Tafinlar

Venclexta

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Pulmonary Embolism

NCT05891886

Clinical

Trials by Indication[1]

Complication1 trial

The Effect of Oxygen Application With Double Nasal Cannula on Respiratory Complications

Unknown status·IInonu University·N/A·NCT06273319·200 enrolled

Kidney Disease1 trial

Oxygen Therapy in Diabetic Kidney Disease

Not yet recruiting·—·N/A·NCT06959485·80 enrolled

Hernia1 trial

The Effect of Ozone Therapy for Lumbar Herniated Disc

Terminated·KKovacs Foundation·Phase 2·NCT00566007·156 enrolled

Pulmonary Embolism1 trial

Supplemental Oxygen in Pulmonary Embolism (SO-PE)

Recruiting·MMassachusetts General Hospital·Phase 1·NCT05891886·80 enrolled

COPD1 trial

Air as a Placebo: Increasing the Respiratory Performance of People With COPD Through Simple Expectations of Improvement

Unknown status·FFondazione Don Carlo Gnocchi Onlus·N/A·NCT05218564·102 enrolled

1 more indication

Oxygenation1 trial

Can High-Flow Oxygen Therapy Improve Oxygenation During Exercise in ILD Patients?

Unknown status·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·N/A·NCT03287713·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for OXYGEN THERAPY. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OXYGEN THERAPY compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OXYGEN THERAPY. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMassachusetts General Hospital

OXYGEN THERAPY

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Complication1 trial

Kidney Disease1 trial

Hernia1 trial

Pulmonary Embolism1 trial

COPD1 trial

Oxygenation1 trial

References

Drug Info

Quick Facts

Related News